Molecular profiling of prostate cancer

Current Urology Reports

Volumn 5, Issue 1, 2004, Pages 45-51

  Huppi, Konrad ^a   Chandramouli, G V R ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

Benign Prostatic Hyperplasia; Prostate Cancer; Prostatic Intraepithelial Neoplasia; Prostatitis; Radical Prostatectomy

Indexed keywords

DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; HUMAN; MALE; METABOLISM; PROSTATE TUMOR; REVIEW;

GENE EXPRESSION PROFILING; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS;

EID: 2142758146     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-004-0011-0     Document Type: Article

References (36)

1. Jewett HJ: The present status of radical prostatectomy for stages A and B prostatic cancer. J Urol 1975, 2:105–124.
2. Gleason D: Classification of prostatic carcinomas. Cancer Chemother Rep 1966, 50:125–128.
3. Stamey TA, Yang N, Hay AR, et al.: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 317:909–916. DOI: 10.1056/NEJM198710083171501
4. Bertucci F, Viens P, Tagett R, et al.: DNA Arrays in clinical oncology: promises and challenges. Lab Invest 2003, 83:305–316.
5. Macgregor PF, Squire JA: Application of microarray to the analysis of gene expression in cancer. Clin Chem 2002, 48:1170–1177.
6. Cole KA, Krizman DB, Emmert-Buck MR: The genetics of cancer: a 3D model. Nat Genet 1999, 21:38–41. DOI: 10.1038/4466
7. Best CJ, Leiva IM, Chuaqui RF, et al.: Molecular differentiation of high-and moderate-grade human prostate cancer by cDNA microarray analysis. Diagn Mol Pathol 2003, 12:63–70. DOI: 10.1097/00019606-200306000-00001
8. Whitney, AR, Diehn M, Popper SJ, et al.: Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci USA 2003, 100:1896–1901. DOI: 10.1073/pnas.252784499
9. Khan J, Wei JS, Ringer M, et al.: Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001, 7:673–679. DOI: 10.1038/89044
10. Tusher VG, Olkin IV, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98:5116–5121. DOI: 10.1073/pnas.091062498
11. Agarwal D, Chen T, Irby R, et al.: Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002 94:513–521.
12. Luo J, Duggan DJ, Chen VD, et al.: Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Can Res 2001, 61:4683–4688. This paper was the first to distinguish PCA from BPH by MOS and weighted gene analysis.
13. Dhanasekaran SM., Barrette TR, Ghosh D, et al.: Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 412:822–826. One of the first and most comprehensive studies of MET, PCA, prostatitis, BPH, and NAP by microarray expression analysis. DOI: 10.1038/35090585
14. Magee JA, Araki T, Patil S, et al.: Expression profiling reveals hepsin overexpression in prostate cancer. Can Res 2001, 61:5692–5696.
15. Chetcuti A, Margan S, Mann S, et al.: Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array. Prostate 2001, 47:132–140. DOI: 10.1002/pros.1056
16. Welsh JB, Sapinoso LM, Su AI, et al.: Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Can Res 2001, 61:5974–5978.
17. Ernst T, Hergenhahn M, Kenzelman M, et al.: Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 2002, 160:2169–2180.
18. Bull JH, Ellison G, Patel A, et al.: Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using microarray. Br J Cancer 2001, 84:1512–1519. DOI: 10.1054/bjoc.2001.1816
19. Singh D, Febbo Pg, Ross K, et al.: Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002, 1:203–209. This paper successfully shows that expression of a group of 29 genes by microarray analysis clustered according to Gleason score, but did not correlate with clinical outcome for prostate cancer. DOI: 10.1016/S1535-6108(02)00030-2
20. Luo J, Yu YP, Cieply K, et al.: Gene expression analysis of prostate cancers. Mol Carcinog 2002, 33:25–35. DOI: 10.1002/mc.10018
21. LaTulippe E, Satagopan J, Smith A, et al.: Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Can Res 2002, 62:4499–4506.
22. Rhodes DR, Barrette TR, Rubin MA, et al.: Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Can Res 2002, 62:4427–4433. This is the first paper that has attempted to establish a statistical metaanalysis model for cross-validating data from four independent microarray experiments on the expression of genes in prostate cancer.
23. Ferdinandusse S, Denis S, Clayton PT: Mutations in the gene encoding peroxisomal alpha-methylacyl-CoA racemase cause adult-onset sensory motor neuropathy. Nat Gen 2000, 24:188–191. DOI: 10.1038/72861
24. Raaphorst FM, van Kemenade FJ, Blokzijl T, et al.: Coexpression of BM-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin’s disease. Am J Pathol 2000, 157:709–715.
25. van Lohuizen M, Verbeek S, Scheijen B, et al.: Identification of cooperating oncogenes in Eu-myc transgenic mice by provirus tagging. Cell 1991, 65:737–752. DOI: 10.1016/0092-8674(91)90382-9
26. Haupt Y, Alexander WS, Barri G, et al.: Novel zinc finger gene implicated as myc collaborator by retrovirally accelerated lymphomagenesis in Eu-myc transgenic mice. Cell 1991, 65:753–763. DOI: 10.1016/0092-8674(91)90383-A
27. Varambally S, Dhanasekaran SM, Zhou M, et al.: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624–629. DOI: 10.1038/nature01075
28. Shimizu K, Nagamachi Y, Tani M, et al.: Molecular cloning of a novel NF2/ERM/4.1 superfamily gene, EHM2, that is expressed in high-metastatic K1735 murine melanoma cells. Genomics 2000, 65:113–120. DOI: 10.1006/geno.2000.6154
29. Shurbaji MS, Kalbfleisch JH, Thurmond TS: Immunohistochemical detection of a fatty acid synthase (OA-519) as a predictor of progression of prostate cancer. Hum Pathol 1996, 27:917–921. DOI: 10.1016/S0046-8177(96)90218-X
30. Rhodes DR, Sanda MG, Otte AP, et al.: Multiplex biomarker approach for determining risk of prostate-specific antigendefined recurrence of prostate cancer. J Natl Cancer Inst 2003, 95:661–668. An interesting paper that incorporates protein expression in the tissue microarray with attempts at combining candidate biomarkers. The results of this study suggest E-cadherin and EZH2 are significantly associated with PCA recurrence after radical prostatectomy. DOI: 10.1093/jnci/95.9.661
31. Kattan MW: Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003, 95:634–635. DOI: 10.1093/jnci/95.9.634
32. Magrath I: Molecular characteristics of diffuse large-b-cell lymphoma. N Engl J Med 2002, 346:1998–1999. DOI: 10.1056/NEJMe020050
33. Rosenwald A, Wright G, Chan WC, et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-b-cell lymphoma. N Engl J Med 2003, 346:1937–1947. DOI: 10.1056/NEJMoa012914
34. vande Vijver MJ, He YD, van’t Veer LJ, et al.: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999–2009. DOI: 10.1056/NEJMoa021967
35. Nielsen TO, West RB, Linn SC, et al.: Molecular characterization of soft tissue tumors: a gene expression study. Lancet 2002, 359:1301–1307. DOI: 10.1016/S0140-6736(02)08270-3
36. Khan J, Simon R, Bittner M, et al.: Gene expression profiling of alveolar rhabdomyosarcoma with cDNA arrays. Cancer Res 1998, 58:5009–5010.